FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:1228-1230 April 23, 1998 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Taipale, P. PubMed Citation

To the Editor: The article by Taipale et al. (Dec. 4 issue)¹ raises further questions regarding methodologic flaws common in the literature on nuchal-translucency screening for Down's syndrome during the first trimester. The principal role of such screening is to detect fetuses with Down's syndrome in the 60 to 70 percent of pregnant women with no other risk factors for aneuploidy — namely, maternal age of more than 35 years or a previous pregnancy with Down's syndrome. Measuring nuchal translucency in women who already have these risk factors constitutes screening of a high-risk group, the results of which may not . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Bigger, J. T. Jr, Whang, W., Rottman, J. N., Kleiger, R. E., Gottlieb, C. D., Namerow, P. B., Steinman, R. C., Estes, N. A. M. III (1999). Mechanisms of Death in the CABG Patch Trial : A Randomized Trial of Implantable Cardiac Defibrillator Prophylaxis in Patients at High Risk of Death After Coronary Artery Bypass Graft Surgery. Circulation 99: 1416-1421 [Abstract] [Full Text]